Pharmaxis CEO and leadership

Gary Phillips was appointed Chief Executive Officer and a member of the Pharmaxis Board of Directors in March 2013. Mr Phillips joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. He served as Commercial Director until June 2008 when he was appointed the company’s Chief Operating Officer. In this role he expanded Pharmaxis’ Commercial infrastructure in Europe and the USA, and worked closely with the clinical development, regulatory approval processes and reimbursement of Pharmaxis products Aridol and Bronchitol. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1998 to 2003, Mr. Phillips held various positions within Novartis Asia Pacific, first as a Regional Manager responsible for the P&L of 8 countries and most recently as Chief Executive Officer of Novartis Pharmaceuticals Australia Pty Ltd, where he successfully launched leading oncology and ophthalmology products and relaunched newly acquired primary care products. From 1992 to 1998, Mr. Phillips served as Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of multiple new products and achieved the leading market share amongst multinational pharmaceutical companies. Gary Phillips holds a B. Pharm. in Pharmacy with honors from Nottingham University in the U.K. and an M.B.A. from Henly Management College.

David McGarvey is a CFO/Secretary at Pharmaxis Ltd and is based in Sydney, New South Wales, Australia. He has experience at Pricewaterhousecoopers LLP and has worked as CFO at USF Filtration & Separation Group, Chief Financial Officer at US Filter Corp, and Chief Financial Officer at Memtec Ltd. David works or has worked as MEMBER at CPA Australia, MEMBER at Australian Society of Certified Practicing Accountants, and MEMBER at Institute of Chartered Accountants in Australia. He studied at Australian Institute of Company Directors between 2016 and 2017, Macquarie University between 1975 and 1978, and Epping Boys High School between 1969 and 1974.

Gary Phillips was appointed Chief Executive Officer and a member of the Pharmaxis Board of Directors in March 2013. Mr Phillips joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. He served as Commercial Director until June 2008 when he was appointed the company’s Chief Operating Officer. In this role he expanded Pharmaxis’ Commercial infrastructure in Europe and the USA, and worked closely with the clinical development, regulatory approval processes and reimbursement of Pharmaxis products Aridol and Bronchitol. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1998 to 2003, Mr. Phillips held various positions within Novartis Asia Pacific, first as a Regional Manager responsible for the P&L of 8 countries and most recently as Chief Executive Officer of Novartis Pharmaceuticals Australia Pty Ltd, where he successfully launched leading oncology and ophthalmology products and relaunched newly acquired primary care products. From 1992 to 1998, Mr. Phillips served as Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of multiple new products and achieved the leading market share amongst multinational pharmaceutical companies. Gary Phillips holds a B. Pharm. in Pharmacy with honors from Nottingham University in the U.K. and an M.B.A. from Henly Management College.

David McGarvey is a CFO/Secretary at Pharmaxis Ltd and is based in Sydney, New South Wales, Australia. He has experience at Pricewaterhousecoopers LLP and has worked as CFO at USF Filtration & Separation Group, Chief Financial Officer at US Filter Corp, and Chief Financial Officer at Memtec Ltd. David works or has worked as MEMBER at CPA Australia, MEMBER at Australian Society of Certified Practicing Accountants, and MEMBER at Institute of Chartered Accountants in Australia. He studied at Australian Institute of Company Directors between 2016 and 2017, Macquarie University between 1975 and 1978, and Epping Boys High School between 1969 and 1974.